Increase in MR-proADM after one year was associated with increased risk of subsequent CHD events ( HR 1.34 , 1.08-1 .66 ) , non-fatal myocardial infarction ( HR 1.50 , 1.12-2 .03 ) , heart failure ( HR 1.78 , 1.37-2 .30 ) and all-cause mortality ( HR 1.31 , 1.04-1 .64 ) .